MediPharm Labs (TSE:LABS)
TSX:LABS
Top Page
MediPharm Labs
(TSX:LABS)
Select Model
Select Model
Rating:49Neutral
Price Target:
C$0.07
▼(-18.75% Downside)
Action:ReiteratedDate:04/05/26
The score is held back primarily by weak financial performance (ongoing losses and negative operating/free cash flow) and a downtrending technical picture (trading below key moving averages with negative MACD). The latest earnings call provides some offset via improving margins, cost discipline, and strong international growth, but near-term headwinds (notably the Veterans Affairs reimbursement cut and continued losses) keep the overall rating in the lower range.
Positive Factors
Regulatory & Manufacturing Credentials
Broad pharmaceutical-grade regulatory approvals create durable market access to regulated export and B2B pharma channels. These credentials raise entry barriers, support higher-margin contract manufacturing, and underpin multi-market growth opportunities over the next 2–6 months and beyond.
Negative Factors
Negative Operating & Free Cash Flow
Persistent negative OCF and FCF indicate the company is burning cash to fund operations and investments. Over a 2–6 month horizon this necessitates continued external funding, asset sales, or cost cuts, constraining strategic flexibility and raising liquidity risk if trends persist.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory & Manufacturing Credentials
Broad pharmaceutical-grade regulatory approvals create durable market access to regulated export and B2B pharma channels. These credentials raise entry barriers, support higher-margin contract manufacturing, and underpin multi-market growth opportunities over the next 2–6 months and beyond.
Read all positive factors
MediPharm Labs (LABS) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$27.35M
Dividend YieldN/A
Average Volume (3M)466.64K
Price to Earnings (P/E)―
Beta (1Y)1.03
Revenue Growth18.06%
EPS Growth34.58%
CountryCA
Employees161
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.00
Shares Outstanding420,755,000
10 Day Avg. Volume458,518
30 Day Avg. Volume466,636
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)0.76
Price to Sales (P/S)0.61
P/FCF Ratio-4.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)C$50.39M
MediPharm Labs Business Overview & Revenue Model
Company Description
MediPharm Labs Corp., a pharmaceutical company, produces and sells pharmaceutical-quality cannabis oil and concentrates, and advanced derivative products in Canada, Australia, Germany, and internationally. It formulates, processes, packages, and d...
How the Company Makes Money
MediPharm Labs primarily makes money by manufacturing cannabis extracts and derivative products and selling them through several channels. A core revenue stream is business-to-business (B2B) supply: MediPharm produces bulk cannabis concentrates (e...
MediPharm Labs Earnings Call Summary
Earnings Call Date:Mar 30, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 18, 2026
Earnings Call Sentiment Positive
The call presented a predominantly positive operational and strategic trajectory: revenue growth (8% YoY) driven by a 43% increase in international medical, margin improvements (Q4 gross margin 35%), cost reductions, stronger liquidity (cash $10.8M) and clear product and market progress (new market entries and pharma-grade launches). However, notable negatives remain — continued net losses (-$8.3M), Q4 revenue dip vs prior year, ongoing pricing compression in key markets, an upcoming Veterans Affairs reimbursement cut, and an interim CEO transition. Taken together, the positives around international growth, regulatory differentiation, expense discipline and strengthened balance sheet materially outweigh the challenges, although risks and near-term headwinds persist.Positive Updates
Full Year Revenue Growth
Full year 2025 revenue of $45.1M, up 8% year-over-year, the highest revenue in five years.
Negative Updates
Q4 Revenue Decline vs Prior Year
Q4 2025 revenue was $11.1M, down from $12.0M in Q4 2024 — decline driven by timing and mix differences in the international medical business.
Read all updates
Q4-2025 Updates
Positive
Negative
Full Year Revenue Growth
Full year 2025 revenue of $45.1M, up 8% year-over-year, the highest revenue in five years.
Read all positive updates
Company Guidance
The company did not give formal 2026 guidance but laid out clear priorities: grow international medical revenue across Germany, the U.K., New Zealand, Brazil, France and Australia (International represented >50% of 2025 revenue, grew 43% YoY and was 55% of Q4 at $6.1M), build international brands, expand pharmaceutical/B2B where returns justify investment, and maintain strict cost discipline while protecting quality and compliance. Management flagged a known headwind—Veteran Affairs Canada cutting the maximum reimbursable price from $8.50/gram to $6.00/gram effective April 1, 2026, which is expected to negatively impact direct-to-patient revenue beginning in Q2 2026—but expects to continue pursuing profitable, sustainable revenue given a strong balance sheet (cash $10.8M, virtually no debt, two facilities appraised >$15M) and recent FY2025 base metrics (revenue $45.1M, gross profit $14.0M at 31% margin, adjusted EBITDA loss $1.6M, net loss $8.3M).MediPharm Labs Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 45.12M | 41.96M | 33.06M | 22.12M | 21.71M |
| Gross Profit | 13.97M | 12.80M | 5.86M | -1.91M | -15.25M |
| EBITDA | -6.54M | -7.52M | -10.48M | -27.09M | -38.55M |
| Net Income | -8.27M | -10.69M | -13.08M | -29.98M | -54.80M |
Balance Sheet | |||||
| Total Assets | 45.74M | 53.73M | 63.94M | 65.50M | 92.36M |
| Cash, Cash Equivalents and Short-Term Investments | 10.81M | 11.69M | 17.98M | 24.14M | 34.11M |
| Total Debt | 201.00K | 388.00K | 2.29M | 632.00K | 216.00K |
| Total Liabilities | 9.93M | 10.55M | 10.93M | 9.49M | 9.21M |
| Stockholders Equity | 35.81M | 43.18M | 53.01M | 56.01M | 83.15M |
Cash Flow | |||||
| Free Cash Flow | -5.60M | -5.01M | -12.81M | -16.93M | -14.00M |
| Operating Cash Flow | -5.50M | -4.86M | -12.34M | -16.07M | -13.21M |
| Investing Cash Flow | 4.62M | 413.00K | 6.87M | 5.16M | 35.00K |
| Financing Cash Flow | -18.00K | -1.85M | -368.00K | 796.00K | 27.80M |
MediPharm Labs Technical Analysis
Negative
0.08
Price Trends
0.07
Negative
0.07
Negative
0.07
Negative
Market Momentum
>-0.01
Positive
48.12
Neutral
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:LABS, the sentiment is Negative. The current price of 0.08 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.07, and above the 200-day MA of 0.07, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 48.12 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:LABS.
MediPharm Labs Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | C$34.26M | 29.79 | 7.78% | ― | 28.55% | ― | |
61 Neutral | C$8.44M | 8.94 | 11.57% | ― | -1.14% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | C$29.96M | -19.43 | -71.80% | ― | -3.94% | -17.62% | |
49 Neutral | C$27.35M | -3.31 | -19.10% | ― | 18.06% | 34.58% | |
47 Neutral | C$18.85M | -7.21 | -68.32% | ― | 2.41% | 74.61% | |
45 Neutral | C$6.92M | -1.86 | ― | ― | 15.64% | 58.47% |
* Healthcare Sector Average
TSE:LABS
MediPharm Labs
0.07
-0.02
-23.53%
TSE:PCLO
PharmaCielo
0.05
-0.04
-47.06%
TSE:OILS
Nextleaf Solutions
0.05
>-0.01
-16.67%
TSE:ROMJ
Rubicon Organics
0.51
0.04
8.51%
TSE:AVCN
Avicanna
0.15
-0.08
-34.78%
TSE:INNO
InnoCan Pharma
6.66
-4.39
-39.73%
MediPharm Labs Corporate Events
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
MediPharm Labs Boosts International Medical Cannabis Revenue and Tightens Costs in 2025
Positive
Mar 30, 2026
MediPharm Labs reported 2025 revenue of $45.1 million, up 8% year over year, with international medical cannabis sales rising 43% to $25.2 million and accounting for more than half of total revenue. Management highlighted a strengthened balance sh...
Business Operations and StrategyFinancial Disclosures
MediPharm Labs Sets March 30 Date for 2025 Results and Investor Call
Neutral
Mar 26, 2026
MediPharm Labs, a specialized pharmaceutical cannabis company focused on precision-based cannabinoid ingredients and derived products for global medical markets, operates GMP-certified, ISO-standard facilities and has expanded its reach through re...
Business Operations and StrategyExecutive/Board Changes
MediPharm Labs Names CFO Greg Hunter Interim CEO as Pidduck Steps Down
Neutral
Jan 19, 2026
MediPharm Labs announced a leadership transition, with Chief Executive Officer David Pidduck stepping down effective January 23, 2026, while remaining on the board, and Chief Financial Officer Greg Hunter taking on the role of interim CEO while re...
Business Operations and StrategyProduct-Related Announcements
MediPharm Labs Enters Costa Rica’s Medical Cannabis Market via Remidose Supply Deal
Positive
Jan 13, 2026
MediPharm Labs has signed a definitive supply agreement with Remidose Aerosols’ Costa Rican affiliate, Remidose LATAM, to export a portfolio of GMP-certified medicinal cannabis products—including oils, tinctures, metered dose inhalers ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.